IBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the provided data, iBio Inc is not a strong buy for a beginner, long-term investor at this moment. Despite some bullish technical indicators, the company's financial performance is weak, with no revenue and negative EPS. Additionally, there are no significant positive catalysts or recent news to support a strong upward movement in the stock price. The lack of significant trading trends, options data, and recent congress trading activity further limits confidence in this stock as a long-term investment.
The technical indicators show a mixed picture. The MACD is positive and expanding, indicating bullish momentum. The RSI is at 87.48, which is in the overbought zone, suggesting the stock may be overvalued in the short term. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the price is above key resistance levels (R1: 2.962, Pivot: 2.54). However, these technicals alone are not sufficient to justify a buy for a long-term investor.
Bullish technical indicators, including positive MACD and bullish moving averages.
There are no recent news updates, significant trading trends, or congress trading activity. RSI indicates the stock is overbought, which could lead to a short-term pullback.
In Q2 2026, revenue dropped to 0 (-100% YoY), net income increased to -$8.993M (+106.07% YoY), and EPS dropped to -0.3 (-37.5% YoY). Gross margin remained at 100%. The financials indicate poor growth and weak performance.
LifeSci Capital initiated coverage with an Outperform rating and a $5 price target on 2025-12-18. However, there are no recent updates or changes in analyst ratings or price targets.
